Gefitinib (iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines

Laryngoscope

Volumn 118, Issue 8, 2008, Pages 1372-1376

  Lopez, Jay Patrick ^a   Wang Rodriguez, Jessica ^b   Chang, Catherine Y ^a   Sneh, Gabriel ^a   Yu, Michael Andrew ^a   Pardo, Francisco S ^c   Aguilera, Joseph ^d   Ongkeko, Weg M ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN DIEGO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anaplastic thyroid cancer; Epidermal; Follicular cancer; Gefitinib; Growth factor receptor; Ionizing radiation; Iressa; Metastasis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; QUINAZOLINE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ANAPLASTIC CARCINOMA; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER TISSUE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIOSENSITIZATION; THYROID CANCER; THYROID FOLLICLE CELL; WESTERN BLOTTING; ADENOCARCINOMA; CARCINOMA; DOWN REGULATION; DRUG ANTAGONISM; DRUG POTENTIATION; METABOLISM; METASTASIS; PATHOLOGY; PHOSPHORYLATION; THYROID TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA, FOLLICULAR; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SYNERGISM; HUMANS; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYROID NEOPLASMS;

EID: 49649096924     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLG.0b013e318172aae4     Document Type: Article

References (15)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15, 698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 1997;79:564-573.
3. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006;13:453-464.
4. Mclver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001;130:1028-1034.
5. Younes MN, Yigitbasi OG, Park YW, et al. Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation. Cancer Res 2005;65:4716-4727.
6. Dinneen SF, Valimaki MJ, Bergstralh EJ, Goellner JR, Gorman CA, Hay ID. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab 1995;80:2041-2045.
7. Ethier SP, Lawrence TS. Epidermal growth factor receptor signaling and response of cancer cells to ionizing radiation. J Natl Cancer Inst 2001;93:890-891.
8. Zhou H, Kim YS, Peletier A, McCall W, Earp HS, Sartor CI. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys 2004;58:344-352.
9. Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 2001;49:427-433.
10. Schiff BA, McMurphy AB, Jasser SA, et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 2004;10: 8594-8602.
11. Dominguez-Escrig JL, Kelly JD, Neal DE, King SM, Davies BR. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res 2004;10:4874-4884.
12. Piechocki MP, Yoo GH, Dibbley SK, Lonardo F. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu. Cancer Res 2007;67: 6825-6843.
13. O'Dwyer PJ, Benson AB III. Epidermal growth factor receptor-targeted therapy in colorectal cancer. Semin Oncol 2002;29:10-17.
14. Martelli AM, Tazzari PL, Tabellini G, et al. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia 2003;17:1794-1805.
15. Soderlund K, Perez-Tenorio G, Stal O. Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiationinduced apoptosis in breast cancer cells. Int J Oncol 2005;26:25-32.